D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

Area of Science:

• Rheumatology
• Dermatology
• Internal Medicine

Background:

• Progressive systemic sclerosis is a chronic autoimmune disease characterized by diffuse sclerodermatous skin changes.
• Early diagnosis and intervention are crucial for managing systemic sclerosis and improving patient outcomes.
• The efficacy of D-penicillamine in treating systemic sclerosis requires further investigation.

Purpose of the Study:

• To evaluate the effectiveness of D-penicillamine in patients with early diffuse systemic sclerosis.
• To compare treatment outcomes between patients receiving D-penicillamine and a control group.

Main Methods:

• A retrospective study comparing 73 patients treated with D-penicillamine for at least 6 months with 45 untreated patients.
• All patients had diffuse sclerodermatous skin changes and disease duration under 3 years.
• Follow-up included assessment of skin thickness, visceral organ involvement, and survival rates.

Main Results:

• D-penicillamine treatment led to a significant decrease in skin thickness (p = 0.07).
• A reduced rate of new visceral organ involvement, particularly kidney involvement, was observed in the D-penicillamine group (p = 0.01).
• Patients treated with D-penicillamine demonstrated a higher 5-year cumulative survival rate (88% vs. 66%, p < 0.05).

Conclusions:

• D-penicillamine therapy is associated with significant clinical improvements in early systemic sclerosis.
• The drug effectively reduces skin thickening and slows visceral organ damage, especially in the kidneys.
• D-penicillamine treatment improves long-term survival in patients with progressive systemic sclerosis.